

Critical Limb Ischemia

Andres Schanzer, MD²
Michael S. Conte, MD^{*,1}

Address

^{*1}Division of Vascular and Endovascular Surgery,
Heart and Vascular Center, University of California,
San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
Email: Michael.conte@ucsfmedctr.org

²University of Massachusetts-Memorial Medical Center,
55 Lake Avenue North, Worcester, MA 01655, USA

Published online: 14 April 2010

© The Author(s) 2010. This article is published with open access at Springerlink.com

Opinion statement

Critical limb ischemia (CLI), defined as chronic ischemic rest pain, ulcers, or gangrene attributable to objectively proven arterial occlusive disease, is the most advanced form of peripheral arterial disease. Traditionally, open surgical bypass was the only effective treatment strategy for limb revascularization in this patient population. However, during the past decade, the introduction and evolution of endovascular procedures have significantly increased treatment options. In a certain subset of patients for whom either surgical or endovascular revascularization may not be appropriate, primary amputation remains a third treatment option. Definitive high-level evidence on which to base treatment decisions, with an emphasis on clinical and cost effectiveness, is still lacking. Treatment decisions in CLI are individualized, based on life expectancy, functional status, anatomy of the arterial occlusive disease, and surgical risk. For patients with aortoiliac disease, endovascular therapy has become first-line therapy for all but the most severe patterns of occlusion, and aortofemoral bypass surgery is a highly effective and durable treatment for the latter group. For infrainguinal disease, the available data suggest that surgical bypass with vein is the preferred therapy for CLI patients likely to survive 2 years or more, and for those with long segment occlusions or severe infrapopliteal disease who have an acceptable surgical risk. Endovascular therapy may be preferred in patients with reduced life expectancy, those who lack usable vein for bypass or who are at elevated risk for operation, and those with less severe arterial occlusions. Patients with unreconstructable disease, extensive necrosis involving weight-bearing areas, nonambulatory status, or other severe comorbidities may be considered for primary amputation or palliative measures.

Introduction

Lower-extremity peripheral arterial disease (PAD) is estimated to affect between 8 million and 10 million Americans [1,2]. This prevalence is expected to increase, not only in the United States, but across the

world as the population ages, cigarette smoking persists, and the epidemic of diabetes mellitus and obesity grows [2]. Critical limb ischemia (CLI), the most advanced form of PAD, is associated with a high risk

of cardiovascular events, including major limb loss, myocardial infarction, stroke, and death [1,3–5]. The likelihood of death has been reported to be as high as 20% within 6 months of CLI diagnosis and surpasses 50% at 5 years post diagnosis [6,7]. These high mortality rates exceed those seen in any other pattern of occlusive disease, including patients with symptomatic coronary artery disease [8, 9], and reflect the severe systemic effects associated with a diagnosis of CLI.

To date, no pharmacologic or biologic therapy has demonstrated efficacy in reversing the circulatory impairment seen in patients with CLI. Therefore, if successful revascularization is not feasible, impaired quality of life, limb loss, and death have been the norm rather than the exception [10•].

The economic impact of this growing burden of PAD is being experienced acutely in the United States and many other nations. A study analyzing Medicare data for 2001 found that \$4.37 billion was spent on PAD-related treatment [2]. In total, PAD-related treatment accounted for approximately 13% of all Medicare

Part A and B expenditures for the PAD-treated cohort, and 2.3% of all Medicare Part A and B annual spending.

The widespread adoption of endovascular procedures by multiple disciplines has significantly increased treatment options [6, 11]. This change in treatment paradigm has been driven by technological advances, as well as by the desire of patients and physicians to reduce procedural risk, albeit with potential tradeoffs of inferior durability and greater cost [6]. Between 1996 and 2006, the number of endovascular lower-extremity interventions in the Medicare population reportedly increased by 230%, whereas the number of bypass procedures decreased by 42% [12].

Despite the enormity of the patient population at risk and the multiple treatment options available, rigorous high-level evidence to support informed clinical decision making in patients with CLI has been lacking. There are few high-quality prospective studies and even fewer randomized controlled clinical trials. In this review, we attempt to summarize the existing evidence guiding therapeutic decision making in CLI.

Treatment

Diet and lifestyle

- No clinical trials have been conducted, or are ongoing, that specifically address the role of diet modifications/supplements in the progression of CLI.
- Lipid abnormalities, including elevated total and low-density lipoprotein (LDL) cholesterol, decreased high-density lipoprotein cholesterol, and hypertriglyceridemia, are strongly associated with lower-extremity PAD. As a result, low-cholesterol diets have been recommended for patients with CLI [13].
- Cigarette smoking is a strong predictor of lower-extremity PAD, with a large number of epidemiologic studies establishing an increased incidence of PAD in smokers compared with nonsmokers. Furthermore, the severity of PAD tends to increase in a dose-dependent manner with the number of cigarettes smoked [14]. Interventions directed at smoking cessation, or decreased usage, are critical [11,13].

Pharmacologic treatment

- To date, no pharmacologic therapy has demonstrated efficacy in reversing the arterial occlusive lesions, or the resulting impaired perfusion, seen in patients with CLI. The Circulase trial (Mitsubishi Pharma Corp, Tokyo, Japan), published in 2006, randomly assigned

379 CLI patients with no revascularization option to receive lipocraprost (parenteral prostaglandin) or placebo. The study treatment was found to confer no benefit (or harm) on the primary study end point, death or amputation above the ankle at 180 days [15].

- Various reports have demonstrated that cardioprotective medications such as statins, β -blockers, angiotensin-converting enzyme inhibitors, and antiplatelet agents are associated with a decreased cardiovascular event rate in patients with PAD [16–21]. However, these studies have been conducted in heterogeneous populations, not specifically in patients with CLI. In a retrospective analysis of 1404 CLI patients who had undergone surgical revascularization, statins were demonstrated to confer a significant survival advantage at 1 year (hazard ratio [HR] for mortality, 0.71; $P=0.03$) [22]. However, optimum dosing and therapeutic targets (eg, LDL cholesterol, C-reactive protein levels) for statin therapy in PAD patients are uncertain, and more clinical trials are needed to determine whether statins have direct beneficial effects in the peripheral circulation (limb). In general, current recommendations for the use of cardioprotective medications in CLI follow published general PAD guidelines [13,19].

Interventional procedures

- Various endoluminal catheter-based devices have been developed for patients with CLI. These evolving technologies include balloon angioplasty, CryoPlasty therapy (Boston Scientific, Natick, MA), stent/stent-graft placement, laser atherectomy, and mechanical atherectomy. Beyond single-center case series demonstrating feasibility and technical success, a paucity of high-level data precludes critical evaluation of these technologies. These results often are difficult to interpret because of differences in patient selection, use of multiple therapeutic modalities, and variable end points with variable study durations. A summary of several of the larger, recent series reporting outcomes of endovascular treatment for patients with CLI is presented in Table 1.
- The Transatlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC II), published in 2006, was developed by an international working group charged with reviewing the literature and putting forth recommendations for the diagnosis and treatment of PAD [11]. All recommendations were assigned a grade based on the level of available evidence to support that recommendation. The working group recommended endovascular therapy as the first-line treatment method for patients with TASC A and B lesions. Of note, this recommendation received a grade C for evidence, which was defined as "...evidence obtained from expert committee reports or opinions....no applicable studies of good quality"[11].
- The BASIL (Bypass Versus Angioplasty in Severe Ischaemia of the Leg) trial, sponsored by the UK National Institute of Health Research Health Technology Assessment program, is the only randomized controlled trial (RCT) comparing open surgical bypass with

Table 1. Recent studies reporting outcomes in patients undergoing endovascular therapy for treatment of critical limb ischemia

Study	Patients, <i>n</i>	Study type	Outcome measure(s)	Event rate, %
Laird et al., 2006 [62]	155	Multicenter series	Amputation-free survival (6 mo)	82
Bosiers et al., 2007 [63]	51	Multicenter series	Amputation-free survival (1 y)	79
DeRubertis et al., 2008 [64]	184	Single-center series	Limb salvage (1 y)	88.3
			Primary patency (1 y)	54±5
			Primary patency (2 y)	43±7
Giles et al., 2008 [65]	176	Single-center series	Freedom from restenosis, reintervention, or amputation (1 y)	39
			Freedom from restenosis, reintervention, or amputation (2 y)	35
			Primary patency (1 y)	53
			Primary patency (2 y)	51
			Limb salvage (3 y)	84
			Survival (1 y)	81
			Survival (3 y)	54
Romiti et al., 2008 [66]	–	Meta-analysis	Primary patency (1 y)	58.1±4.6
			Primary patency (3 y)	48.6±8.0
			Secondary patency (1 y)	68.2±5.9
			Secondary patency (3 y)	62.9±11.0
			Limb salvage (1 y)	86.0±2.7
			Limb salvage (3 y)	82.4±3.4
			Survival (1 y)	87.0±2.1
			Survival (3 y)	68.4±5.5

endovascular therapy in patients with severe limb ischemia (SLI) due to infrainguinal disease; therefore, it is worth considering in detail [6]. The term *SLI* was used to “admit patients with chronic, potentially limb threatening, ischemia but who did not necessarily have ankle pressures less than 50 mmHg and thus did not strictly fulfill the requirements of the term *CLI*” [6]. It also is important to note that patients were eligible for BASIL if they were deemed suitable for either angioplasty or bypass and if they met the investigators’ criterion of “grey area of clinical equipoise.”

- The BASIL trial began enrollment in 1999 and randomly assigned 452 patients from 27 centers across Scotland and England. In 2005, the BASIL trialists reported an analysis of outcomes out to 2 years—demonstrating no difference in overall survival or amputation-free survival by intention-to-treat analysis between surgical bypass and endovascular therapy, with surgery being more expensive in the short term [6]. However, post hoc analysis demonstrated that beyond 2 years, patients initially assigned to open bypass surgery had a significantly improved amputation-free survival (adjusted HR, 0.37; 95% CI, 0.17–0.77; $P=0.008$) and reduced all-cause mortality (adjusted HR, 0.34; 95% CI, 0.17–0.71; $P=0.004$) relative to angioplasty [6]. This finding of the BASIL trial was considered significant enough to warrant funding of an extension study, the results of which were

reported recently [23,24,25•,26,27•]. For the overall follow-up period (mean follow-up, 3.1 years; range, 1–5.7 years), there was no significant difference in overall survival or amputation-free survival by intention-to-treat analysis. However, for patients surviving to 2 years post procedure (70% of the study cohort), initial randomization to open bypass was associated with significantly improved overall survival (mean gain of 7.3 months; $P=0.02$) and a trend toward increased amputation-free survival (mean gain of 5.9 months; $P=0.06$). The investigators also published the trial outcomes using an as-treated analysis [25•], an approach that accounts for early treatment cross-overs but, importantly, sacrifices the power of randomization. In this analysis, they found that among patients assigned to open surgery, those who received prosthetic grafts (25% of the surgical group) experienced reduced amputation-free survival compared with those who received vein grafts ($P=0.003$). They also observed that patients who underwent bypass surgery after an initial failed angioplasty experienced significantly worse amputation-free survival than those who underwent bypass as the initial therapy ($P=0.006$), suggesting a real potential downside to failed angioplasty in SLI.

- The primary recommendations from the BASIL trial perhaps are best summarized by the authors in the following statement:
 - “...SLI patients predicted to live more than 2 years, and with a useable vein, should usually have bypass surgery first. This is because the long term results of saphenous vein bypass surgery are good, the rate of balloon angioplasty failure is high, and the results of bypass surgery after failed balloon angioplasty are significantly worse than for bypass surgery. However, patients expected to live less than 2 years, and those without a useable vein, should usually have balloon angioplasty first as they will not survive to reap the longer term benefits of surgery and the results of prosthetic bypass surgery are poor” [25•].
- There are several important limitations and controversies surrounding the application of the BASIL trial to current practice [28], yet this study stands as a seminal RCT in the field of advanced limb ischemia and a basis for the design of future trials.

Endovascular treatment of CLI

Standard procedure(s)	Percutaneous angioplasty with or without adjunctive atherectomy (mechanical or laser) and with or without adjunctive stenting.
Contraindications	Relative: low estimated glomerular filtration rate, anatomically unfavorable disease (common femoral artery lesion, extensive calcification, long segment occlusions, severe popliteal and/or infrapopliteal disease).
Complications	Thrombosis, embolization, blue toe syndrome, amputation, loss of surgical target for bypass, access site complications (hemorrhage, pseudoaneurysm, arteriovenous fistula), contrast nephropathy, and renal failure.

Special points Techniques for endovascular treatment in the aortoiliac segment have become more standardized and durability more consistent for TASC A to TASC C disease (absence of a long segment occlusion for a complete description of TASC criteria, please see Norgren et al. [10•]). Adequate treatment of the common and profunda femoris arteries is of primary importance in CLI and may require a hybrid or fully open approach (eg, femoral endarterectomy). The role of covered stents in the aortoiliac segment is poorly defined. For infrainguinal therapy, treatments and results are more heterogeneous. Several devices are available for different lesion anatomies and technical circumstances (eg, best approach for complete total occlusions), but little evidence is available to support one over the other. The benefit of routine use of nitinol stents in the superficial femoral artery is still under debate [29]. No RCT data are available demonstrating a benefit for the use of stents in popliteal or distal vessels, or for the use of drug-eluting stents in lower-extremity vessels.

Cost/cost-effectiveness Several cost-effectiveness analyses have been performed comparing endovascular therapy with open surgery in patients with CLI [24, 30]. Stoner et al. [30] analyzed 381 femoropopliteal revascularization procedures (open bypass, $n=183$; endovascular, $n=198$) performed for claudication and CLI. In the subset of patients with CLI, they reported an initial cost saving with endovascular therapy (\$7176 vs \$13,277; $P<0.001$). However, during the 1-year study period, the patients who were treated with endovascular therapy went on to require reinterventions, so this cost saving ultimately was lost at 1 year. Similarly, in the cost-effectiveness study that accompanied the BASIL trial, no significant difference was seen, as the survival, hospital costs, and health-related quality-of-life differences were minimal between the surgical and endovascular study arms [24].

Surgery

- Open surgical bypass using autogenous vein traditionally has been the gold-standard revascularization technique for patients with CLI due to infrainguinal disease. However, this paradigm is evolving as new endovascular technologies are being developed, used, and tested.
- Aortofemoral bypass using prosthetic conduit is a standard surgical approach for extensive (eg, TASC D) aortoiliac disease or in the setting of failed prior endovascular therapy. Expected operative mortality is approximately 3% and durability is excellent (85%–90% patency at 5 years and beyond).
- As noted earlier, adequate treatment of disease in the common and deep femoral arteries (eg, endarterectomy and/or patch angioplasty) at the time of either inflow or outflow reconstruction is of primary importance for the long-term fate of the limb in CLI patients.
- Two RCTs examining novel CLI treatments (gene therapy [31] and prostaglandin therapy [15]), a multicenter prospectively maintained vascular registry [32], and one RCT comparing balloon angioplasty with surgical bypass in patients with CLI (BASIL) [6] have provided a wealth of high-quality outcomes data pertaining to vein bypass surgery in patients with CLI. Several authors have used the information contained in these surgical CLI datasets to further our understanding of risk stratification and outcome prediction [22,33–39,40•],

- quality of life [41], disparities in care [42], reintervention rates and the associated outcomes [43], and resource utilization [41].
- Both BASIL [6] and PREVENT III (PIII) [31] challenge the nihilistic paradigms about mortality rates in patients with CLI: 85% of PIII patients survived beyond 1 year, and 70% of BASIL patients survived longer than 2 years. These data suggest that CLI patients may be done a tremendous disservice if the selection of their therapies is founded on the concept that all CLI patients carry a substantial mortality risk that warrants a short-term approach.
 - A recent meta-analysis in patients with CLI undergoing infrainguinal bypass demonstrated 5-year primary patency, secondary patency, and limb salvage rates of 63%, 71%, and 78%, respectively [44]. Recently, a working group under the auspices of the Society for Vascular Surgery used pooled data from the PIII, BASIL, and Circulase studies to develop expected outcomes for vein bypass surgery as the relevant standard for comparing new devices. This group endorsed a set of three safety and six efficacy objective performance goals for CLI based on the pooled data from these surgical controls [40•]. These outcomes are summarized in Table 2.
 - Given the relative high-risk nature of the CLI patient population, as well as the variety of available treatment options, the ability to use

Table 2. Suggested end point definitions for revascularization in critical limb ischemia and expected event rates for open bypass surgery^a

End point	Definition	Event rate, % (95% CI)
Safety outcomes (30 d)		
MACE	Myocardial infarction, stroke, or death (any cause)	6.2 (4.7–8.1)
MALE	Above-ankle amputation of the index limb or <i>major</i> reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis)	6.1 (4.6–7.9)
Amputation	Above-ankle amputation of the index limb	1.9 (1.1–3.1)
Efficacy outcomes (1 y) ^b		
Perioperative death or MALE	Perioperative death (30 d) or any MALE	76.9 (74.0–79.9)
Amputation-free survival	Above-ankle amputation of the index limb or death (any cause)	76.5 (73.7–79.5)
Reintervention, amputation, or stenosis	Any reintervention, above-ankle amputation of the index limb, or stenosis	46.5 (42.3–51.2)
Reintervention or amputation	Any reintervention or above-ankle amputation of the index limb	61.3 (58.0–64.9)
Limb salvage	Freedom from above-ankle amputation	88.9 (86.7–91.1)
Survival	Freedom from death (any cause)	85.7 (83.3–88.1)

^aReported by the Society for Vascular Surgery Working Group for the development of objective performance goals for evaluating catheter-based treatment [40]•. Data are pooled from prospective trials of vein bypass surgery in critical limb ischemia. Additional data are available at <http://www.criticallimb.org/>.

^bAll rates are freedom from event.

MACE major adverse cardiovascular events, MALE major adverse limb events

preprocedure variables to predict a given outcome has become increasingly important. Several recent advances have been made in an attempt to improve individual patient risk prediction at the time of initial patient evaluation. The PIII CLI risk score is an easy-to-use risk stratification model developed to predict amputation-free survival in CLI patients undergoing open infrainguinal surgical bypass [45]. This prediction tool was derived from the cohort of patients who underwent autogenous vein bypass for CLI in the context of the PIII randomized trial [46]. The PIII CLI risk score was then validated both internally, using the trial cohort, and externally, using a multicenter retrospective cohort of patients (total $n = 3286$). In this study, the PIII CLI risk score was found to be a highly reliable and simple tool for stratifying CLI patients selected to undergo bypass surgery into low-, medium-, and high-risk categories. At the time of a patient's initial presentation, five easily obtainable binary variables may be used to provide patients and providers with a valid estimate of the likelihood of amputation-free survival at 1 year after surgical revascularization. These variables are dialysis dependency, tissue loss, advanced age, advanced coronary artery disease, and low hematocrit. Numerous key publications have identified predictors of specific outcomes in case series of patients with CLI (Table 3). When looked at comprehensively, it becomes clear that patency and limb salvage outcomes are, for the most part, linked to characteristics of the bypass graft (ie, type of conduit) and the specific patient anatomy (ie, adequacy of runoff score). In contrast, mortality and functional outcomes appear to be more influenced by systemic comorbidities, preoperative medications, and physiologic characteristics.

Surgical treatment of CLI

Standard procedure(s)	Lower-extremity bypass grafting with or without femoral endarterectomy, with or without adjunctive inflow (aortoiliac) treatment. The preferred conduit for infrainguinal bypass is autogenous saphenous vein followed by other autogenous venous conduits. Prosthetic or other nonautogenous conduits should be considered significantly inferior secondary choices for infrainguinal bypass in the CLI patient.
Contraindications	Unacceptable surgical risk (eg, multiple comorbidities, advanced age), advanced tissue loss on weight-bearing surface, nonambulatory status, no identifiable target vessel with runoff to ankle/foot. Relative contraindications: lack of adequate-quality autogenous vein conduit for infrageniculate bypass, poor-quality target vessel, extensive infection or necrosis compromising graft or vessel coverage.
Special points	The inflow artery must have uncompromised hemodynamics, and arterial outflow should be continuous to the ankle and foot. Vein graft origin (saphenous vein is superior to all other venous conduits for infrainguinal reconstruction), graft diameter, and graft length all are key variables influencing short-term and long-term patency [39]. Reversed, nonreversed, or in situ vein configurations all are effective, and the choice is dictated primarily by surgeon preference and anatomic circumstances.
Cost/cost-effectiveness	See "Cost/cost-effectiveness" under "Endovascular treatment of CLI."

Table 3. Recent studies identifying independent predictors for select outcomes in patients with critical limb ischemia

Study	Patients, <i>n</i>	Study type	Inclusion criterion	Primary outcome measure	Significant predictors
Robinson et al., 2009 [67]	1646	Single-center series	Bypass surgery for CLI or claudication	Patency	High-risk conduit, CLI, smoking, age ≥ 65 y, African American, female
Schanzer et al., 2007 [39]	1404	Multicenter RCT	Bypass surgery for CLI	Patency	Graft diameter, graft length, non-single segment GSV, popliteal artery origin
Bradbury et al., 2010 [23]	452	Multicenter RCT	Bypass surgery and angioplasty for SLI	Death	Age, MI, stroke, tissue loss, ankle pressure, number of detectable ankle pressures, creatinine, smoking, BMI, Bollinger score, diabetes
Goodney et al., 2010 [37]	2036	Multicenter registry	Bypass surgery for CLI or claudication	Death	CHF, diabetes, CLI, absence of single-segment GSV, age >80 y, dialysis, emergent procedure
Schanzer et al., 2008 [22]	1404	Multicenter RCT	Bypass surgery for CLI	Death	Statin therapy, age ≥ 75 y, CAD, CKD stage 4/5, tissue loss
Owens et al., 2007 [68]	456	Single-center series	Bypass surgery for CLI or claudication	Death	Age, CKD stage 4/5
Schanzer et al., 2009 [36]	1166	Multicenter registry	Bypass surgery for CLI	Amputation-free survival	Age ≥ 75 y, dialysis, tissue loss, anemia, advanced CAD
Schanzer et al., 2008 [45]	1404	Multicenter RCT	Bypass surgery for CLI	Amputation-free survival	Age ≥ 75 y, dialysis, tissue loss, anemia, advanced CAD
Biancari et al., 2007 [69]	3925	Multicenter registry	Bypass surgery for CLI	Amputation-free survival	Diabetes, CAD, foot gangrene, urgent operation
Goodney et al., 2009 [34, 35]	2036	Multicenter registry	Bypass surgery for CLI or claudication	Amputation or loss of secondary patency	Age 40–49 y, nonambulatory preoperatively, dialysis, diabetes, CLI, composite vein grafts, tarsal bypass target, nursing home preoperatively
Rossi et al., 2003 [70]	468	Single-center series	Bypass surgery for CLI or claudication or aneurysm	Amputation	Gender, nonautologous conduit, redo bypass
Toursarkissian et al., 2002 [71]	124	Single-center series	Bypass surgery for CLI or claudication	Amputation	Angiographic score, foot score, diabetes
Alback et al., 1998 [72]	132	Single-center series	Bypass surgery for CLI or claudication	Amputation	“Ad hoc” grading system of outflow arteries

Table 3. (continued)

Study	Patients, <i>n</i>	Study type	Inclusion criterion	Primary outcome measure	Significant predictors
Simons et al., 2010 [73]	1457	Multicenter registry	Bypass surgery for CLI	Clinical failure (persistent symptoms and/or amputation) despite bypass patency	Dialysis, preoperative ambulation with assistance, history of CABG or PCI
Goodney et al., 2009 [34]	1400	Multicenter registry	Bypass surgery for CLI or claudication	Ambulatory failure	Nonambulatory preoperatively, CLI, age ≥ 70 y, postoperative MI, postoperative amputation
Taylor et al., 2006 [74]	1000	Single-center series	Bypass surgery for CLI	Ambulatory deterioration/failure	Female, diabetes, renal insufficiency, dementia, homebound preoperatively, postoperative amputation
Nguyen et al., 2006 [41]	1404	Multicenter RCT	Bypass surgery for CLI	Decreased improvement in quality of life	Diabetes, postoperative graft-related event
Taylor et al., 2006 [74]	1000	Single-center series	Bypass surgery for CLI	Non-independent living	Age ≥ 70 y, ulceration, previous stroke, dementia, nonambulatory, postoperative amputation

BMI body mass index, *CABG* coronary artery bypass grafting, *CAD* coronary artery disease; *CHF* congestive heart failure, *CKD* chronic kidney disease, *CLI* critical limb ischemia, *GSV* great saphenous vein, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *RCT* randomized controlled trial, *SLI* severe limb ischemia

Other treatments

- Although hyperbaric therapy commonly is used for nonhealing wounds, its efficacy has not yet been established in patients with CLI. It may be of limited utility in patients in whom revascularization is not technically feasible or for those who have failed all previous revascularization attempts.
- Spinal cord stimulation has been proposed as an alternative to primary amputation in CLI patients with ischemic rest pain who are not amenable to revascularization. This technique requires the implantation of a subcutaneous pulse generator that stimulates electrodes at the L3-L4 level. Although this technique has not enjoyed widespread use, a recent meta-analysis did demonstrate significant pain reduction and an 11% reduced amputation rate compared with medical therapy alone [47]. The role for this therapy presently is unclear.
- Intermittent pneumatic compression in patients with CLI is another proposed therapy for augmenting distal arterial oxygen delivery in

those who are not amenable to revascularization. Preliminary investigations have demonstrated increased muscular, collateral, and skin blood flow in patients receiving compression therapy [48]. Furthermore, a small study comparing CLI patients receiving compression therapy ($n=24$) with those receiving optimal medical management ($n=24$) did demonstrate that compression therapy was associated with improved wound healing, limb salvage, and transcutaneous oximetry [49]. Larger studies are needed to determine a role for intermittent pneumatic compression in CLI.

Emerging therapies

- New revascularization strategies for CLI patients not amenable to either endovascular or surgical revascularization are being explored. Based on an increased mechanistic understanding of angiogenesis and arteriogenesis, novel therapeutic approaches including molecular, genetic, and cell-based treatments have entered the clinical trial phase [50].
- In the PIII study, published in 2006, 1404 CLI patients undergoing bypass surgery were randomly assigned to receive edifoligide (a DNA molecule that inhibits cell cycle gene expression and was hypothesized to reduce neointimal hyperplasia) or placebo. The study treatment was found to confer no benefit or harm on either the primary study end point of time to index graft reintervention or major amputation or the secondary end points of all-cause graft failure, significant graft stenosis, amputation/reintervention-free survival, and nontechnical primary graft patency [31].
- Several gene therapy RCTs using hepatocyte growth factor [51], fibroblast growth factor [52], and vascular endothelial growth factor [53–55] have been carried out in an attempt to activate the angiogenesis pathway. Preliminary data from these studies suggest limited gains. In one study, the authors demonstrated improvement in their primary study end point (improvement in the angiographic indices 3 months after vascular endothelial growth factor gene transfer) [54]. In a phase 2 double-blind RCT, intramuscular injection of hepatocyte growth factor plasmid in 104 CLI patients demonstrated safety, and transcutaneous oxygen levels increased at 6 months in the high-dose group [51]. Nikol et al. [52] reported a European phase 1/2 RCT examining a plasmid-based fibroblast growth factor gene delivery approach in 125 CLI patients; there was no significant difference in the primary end point (ulcer healing), but amputation-free survival was improved. Larger RCTs are required in the field, but significant challenges in study design, recruitment, and costs have slowed progress in this area.
- Cell therapy is a regenerative medical approach for CLI aimed at enhancing angiogenesis. Cell therapy trials to date have included relatively few patients compared with gene therapy trials. Nonetheless, the preliminary findings are encouraging. Autologous cells of various sources (eg, peripheral blood, bone marrow, adipose tissue)

and cell type (endothelial progenitors, mesenchymal stem cells, peripheral blood mononuclear cells) have been used in phase 1/2 investigations in CLI. Bone marrow mononuclear cells injected into the gastrocnemius [56] and intra-arterial infusion of circulating blood-derived progenitor cells [57] both have been associated with improvements in prespecified primary end points. There are several ongoing studies in this area.

- Drug-eluting balloons and stents have undergone limited evaluation in the lower-extremity circulation to date. Recent reports of superficial femoral artery angioplasty using a paclitaxel-coated balloon have shown encouraging results [58–60], and further trials are planned in the CLI population. Drug-eluting stents are being evaluated in the femoral and infrapopliteal arteries. No data are available yet on the utility of these technologies for CLI.
- Bioresorbable stents offer the potential to prevent recoil post angioplasty, improve remodeling, and eliminate the long-term inflammatory response to the implant. This technology is in an early stage. An initial trial of a bioresorbable stent for infrapopliteal disease in CLI patients failed to show any significant benefit [61].

Disclosure

No potential conflicts of interest relevant to this article were reported.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
 - Of major importance
1. Criqui MH, Langer RD, Fronek A, et al.: **Mortality over a period of 10 years in patients with peripheral arterial disease.** *N Engl J Med* 1992, 326:381–386.
 2. Hirsch AT, Hartman L, Town RJ, Virnig BA: **National health care costs of peripheral arterial disease in the Medicare population.** *Vasc Med* 2008, 13:209–215.
 3. McKenna M, Wolfson S, Kuller L: **The ratio of ankle and arm arterial pressure as an independent predictor of mortality.** *Atherosclerosis* 1991, 87:119–128.
 4. Murabito JM, Evans JC, Nieto K, et al.: **Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.** *Am Heart J* 2002, 143:961–965.

5. Howell MA, Colgan MP, Seeger RW, et al.: **Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study.** *J Vasc Surg* 1989, 9:691–696; discussion 696–697.
 6. Adam DJ, Beard JD, Cleveland T, et al.: **Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.** *Lancet* 2005, 366:1925–1934.
 7. Stoyioglou A, Jaff MR: **Medical treatment of peripheral arterial disease: a comprehensive review.** *J Vasc Interv Radiol* 2004, 15:1197–1207.
 8. Steg PG, Bhatt DL, Wilson PW, et al.: **One-year cardiovascular event rates in outpatients with atherosclerosis.** *JAMA* 2007, 297:1197–1206.
 9. Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: **The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database.** *BMC Cardiovasc Disord* 2005, 5:14.
 10. Norgren L, Hiatt WR, Dormandy JA, et al.: **TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).** *J Vasc Surg* 2007, 45(Suppl S):S5–S67.
- These are the current guidelines for treatment from the Transatlantic Inter-Society Working Group.
11. DeRubertis BG, Faries PL, McKinsey JF, et al.: **Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions.** *Ann Surg* 2007, 246:415–422; discussion 422–424.
 12. Goodney PP, Beck AW, Nagle J, et al.: **National trends in lower extremity bypass surgery, endovascular interventions, and major amputations.** *J Vasc Surg* 2009, 50:54–60.
 13. Hirsch AT, Haskal ZJ, Hertzner NR, et al.: **American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.** *Circulation* 2006, 113:e463–e654.
 14. Price JF, Mowbray PI, Lee AJ, et al.: **Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study.** *Eur Heart J* 1999, 20:344–353.
 15. Brass EP, Anthony R, Dormandy J, et al.: **Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia.** *J Vasc Surg* 2006, 43:752–759.
 16. Heart Protection Study Collaborative Group: **MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial.** *Lancet* 2002, 360:7–22.
 17. Feringa HH, Karagiannis SE, van Waning VH, et al.: **The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.** *J Vasc Surg* 2007, 45:936–943.
 18. Schillinger M, Exner M, Mlekusch W, et al.: **Statin therapy improves cardiovascular outcome of patients with peripheral artery disease.** *Eur Heart J* 2004, 25:742–748.
 19. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. **Antiplatelet Trialists' Collaboration.** *BMJ* 1994, 308:81–106.
 20. Antithrombotic Trialists' Collaboration: **Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.** *BMJ* 2002, 324:71–86.
 21. Mangano DT, Layug EL, Wallace A, Tateo I: **Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group.** *N Engl J Med* 1996, 335:1713–1720.
 22. Schanzer A, Hevelone N, Owens CD, et al.: **Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia.** *J Vasc Surg* 2008, 47:774–781.
 23. Bradbury A, Adam DJ, Bell J, et al.: **Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making.** *J Vasc Surg* 2010 (In press).

24. Forbes J, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischemia of the leg (BASIL) trial: health-related quality of life, resource utilization and cost-effectiveness analysis. *J Vasc Surg* 2010 (In press).
25. • Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. *J Vasc Surg* 2010 (In press). This article discusses long-term follow-up in the BASIL trial by treatment received.
26. Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a description of the severity and extent of disease using the Bollinger angiogram scoring method and the TASC II classification. *J Vasc Surg* 2010 (In press).
27. • Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention to treat analysis of amputation free and overall survival in patients randomised to a bypass surgery first or a balloon angioplasty first strategy. *J Vasc Surg* 2010 (In press).
This article discusses long-term follow-up in the BASIL trial by treatment assigned.
28. Conte MS: BASIL and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. *J Vasc Surg* 2010 (In press).
29. Kasapis C, Henke PK, Chetcuti SJ, et al.: Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. *Eur Heart J* 2009, 30:44–55.
30. Stoner MC, Defreitas DJ, Manwaring MM, et al.: Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. *J Vasc Surg* 2008, 48:1489–1496.
31. Conte MS, Bandyk DF, Clowes AW, et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg* 2006, 43:742–751; discussion 751.
32. Cronenwett JL, Likosky DS, Russell MT, et al.: A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). *J Vasc Surg* 2007, 46:1093–1101; discussion 101–102.
33. Conte MS, Bandyk DF, Clowes AW, et al.: Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. *J Vasc Surg* 2005, 42:456–464; discussion 464–465.
34. Goodney PP, Likosky DS, Cronenwett JL: Predicting ambulation status one year after lower extremity bypass. *J Vasc Surg* 2009, 49:1431–9 e1.
35. Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with amputation or graft occlusion 1 year after lower extremity bypass in northern New England. *Ann Vasc Surg* 2010, 24:57–68.
36. Schanzer A, Goodney PP, Li Y, et al.: Validation of the PIII CLI risk score for the prediction of amputation-free survival in patients undergoing infrainguinal autogenous vein bypass for critical limb ischemia. *J Vasc Surg* 2009, 50:769–775; discussion 775.
37. Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with death 1 year after lower extremity bypass in northern New England. *J Vasc Surg* 2010, 51:71–78.
38. Nguyen LL, Brahmanandam S, Bandyk DF, et al.: Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. *J Vasc Surg* 2007, 46:1191–1197.
39. Schanzer A, Hevelone N, Owens CD, et al.: Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. *J Vasc Surg* 2007, 46:1180–1190; discussion 1190.
40. • Conte MS, Geraghty PJ, Bradbury AW, et al.: Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. *J Vasc Surg* 2009, 50:1462–73.e3.
This article provides suggested performance goals for devices targeting CLI, generated by a working group from the Society for Vascular Surgery.
41. Nguyen LL, Moneta GL, Conte MS, et al.: Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. *J Vasc Surg* 2006, 44:977–983; discussion 983–984.
42. Nguyen LL, Hevelone N, Rogers SO, et al.: Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. *Circulation* 2009, 119:123–130.
43. Berceli SA, Hevelone ND, Lipsitz SR, et al.: Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. *J Vasc Surg* 2007, 46:1173–1179.
44. Albers M, Romiti M, Brochado-Neto FC, et al.: Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. *J Vasc Surg* 2006, 43:498–503.
45. Schanzer A, Mega J, Meadows J, et al.: Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. *J Vasc Surg* 2008, 48:1464–1471.
46. Conte MS, Lorenz TJ, Bandyk DF, et al.: Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. *Vasc Endovasc Surg* 2005, 39:15–23.

47. Ubbink DT, Vermeulen H: **Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia.** *Cochrane Database Syst Rev* 2003, CD004001.
48. Labropoulos N, Leon Jr LR, Bhatti A, et al.: **Hemodynamic effects of intermittent pneumatic compression in patients with critical limb ischemia.** *J Vasc Surg* 2005, 42:710–716.
49. Kavros SJ, Delis KT, Turner NS, et al.: **Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up.** *J Vasc Surg* 2008, 47:543–549.
50. Sneider EB, Nowicki PT, Messina LM: **Regenerative medicine in the treatment of peripheral arterial disease.** *J Cell Biochem* 2009, 108:753–761.
51. Powell RJ, Simons M, Mendelsohn FO, et al.: **Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.** *Circulation* 2008, 118:58–65.
52. Nikol S, Baumgartner I, Van Belle E, et al.: **Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.** *Mol Ther* 2008, 16:972–978.
53. Rajagopalan S, Mohler 3rd ER, Lederman RJ, et al.: **Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.** *Circulation* 2003, 108:1933–1938.
54. Makinen K, Manninen H, Hedman M, et al.: **Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.** *Mol Ther* 2002, 6:127–133.
55. Kusumanto YH, van Weel V, Mulder NH, et al.: **Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial.** *Hum Gene Ther* 2006, 17:683–691.
56. Tateishi-Yuyama E, Matsubara H, Murohara T, et al.: **Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.** *Lancet* 2002, 360:427–435.
57. Lenk K, Adams V, Lurz P, et al.: **Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia.** *Eur Heart J* 2005, 26:1903–1909.
58. Tepe G, Schmitmeier S, Speck U, et al.: **Advances on drug-coated balloons.** *J Cardiovasc Surg (Torino)* 2010, 51:125–143.
59. Scheller B, Speck U: **Potential solutions to the current problem: coated balloon.** *EuroIntervention* 2008, 4:C63–C66.
60. Tepe G, Zeller T, Albrecht T, et al.: **Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.** *N Engl J Med* 2008, 358:689–699.
61. Bosiers M, Peeters P, D'Archambeau O, et al.: **AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis.** *Cardiovasc Intervent Radiol* 2009, 32:424–435.
62. Laird JR, Zeller T, Gray BH, et al.: **Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial.** *J Endovasc Ther* 2006, 13:1–11.
63. Bosiers M, Deloose K, Verbist J, Peeters P: **Nitinol stenting for treatment of 'below-the-knee' critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation.** *J Cardiovasc Surg* 2007, 48:455–461.
64. DeRubertis BG, Pierce M, Ryer EJ, et al.: **Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia.** *J Vasc Surg* 2008, 47:101–108.
65. Giles KA, Pomposelli FB, Spence TL, et al.: **Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs.** *J Vasc Surg* 2008, 48:128–136.
66. Romiti M, Albers M, Brochado-Neto FC, et al.: **Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia.** *J Vasc Surg* 2008, 47:975–981.
67. Robinson 3rd WP, Owens CD, Nguyen LL, et al.: **Inferior outcomes of autogenous infrainguinal bypass in Hispanics: an analysis of ethnicity, graft function, and limb salvage.** *J Vasc Surg* 2009, 49:1416–1425.
68. Owens CD, Ho KJ, Kim S, et al.: **Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification.** *J Vasc Surg* 2007, 45:944–952.
69. Biancari F, Salenius JP, Heikkinen M, et al.: **Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a Finnvasc registry study.** *World J Surg* 2007, 31:217–225; discussion 226–227.
70. Rossi PJ, Skelly CL, Meyerson SL, et al.: **Redo infrainguinal bypass: factors predicting patency and limb salvage.** *Ann Vasc Surg* 2003, 17:492–502.

71. Toursarkissian B, D'Ayala M, Stefanidis D, et al.: **Angiographic scoring of vascular occlusive disease in the diabetic foot: relevance to bypass graft patency and limb salvage.** *J Vasc Surg* 2002, 35:494–500.
72. Alback A, Biancari F, Saarinen O, Lepantalo M: **Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score.** *Eur J Vasc Endovasc Surg* 1998, 15:220–224.
73. Simons J, Goodney PG, Nolan B, et al.: **Failure to achieve clinical improvement despite graft patency in patients undergoing lower extremity bypass for critical limb ischemia.** *J Vasc Surg* 2010 (In press).
74. Taylor SM, Kalbaugh CA, Blackhurst DW, et al.: **Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions.** *J Vasc Surg* 2006, 44:747–755; discussion 755–756.